Drugs / Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)
Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06224608 | Jan → May 2023 | tuberculosis | Chengdu CoenBiotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06224608 ↗ |
| Modality | Protein / enzyme biologic | “Fusion Protein” NCT06224608 ↗ |